MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.065
+0.015
+1.43%
Opening 12:26 06/11 EDT
OPEN
1.040
PREV CLOSE
1.050
HIGH
1.065
LOW
1.040
VOLUME
22.38K
TURNOVER
--
52 WEEK HIGH
1.945
52 WEEK LOW
0.9520
MARKET CAP
33.41M
P/E (TTM)
-1.4158
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0601-0605)?
Weekly Report · 3d ago
Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026
TipRanks · 06/03 13:39
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential
Benzinga · 06/03 12:11
Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting
Benzinga · 06/03 11:29
Actinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
TipRanks · 06/03 11:07
Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer
TipRanks · 06/01 12:52
Press Release: Actinium Appoints Accomplished -2-
Dow Jones · 06/01 12:00
Press Release: Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Dow Jones · 06/01 12:00
More
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.